WEBVTT

1
00:00:00.080 --> 00:00:03.759
<v Speaker 1>Hi, Tracy, Welcome. I'm Valerie Bowling. I'm the executive director

2
00:00:03.839 --> 00:00:06.799
<v Speaker 1>over at the Conference Forum, and I'm with Tracy Kimball,

3
00:00:06.799 --> 00:00:10.519
<v Speaker 1>who is the director of DEFARM, and we are delighted

4
00:00:10.560 --> 00:00:14.960
<v Speaker 1>to bring forward information about a particular section of the

5
00:00:15.039 --> 00:00:19.760
<v Speaker 1>conference called Pharma from the Trenches. So DEFARM, which stands

6
00:00:19.800 --> 00:00:24.399
<v Speaker 1>for Disruptive Innovations to Modernize Clinical Trials, is happening September

7
00:00:24.440 --> 00:00:28.000
<v Speaker 1>sixteenth and seventeenth in Philadelphia at the Loew's Hotel. And

8
00:00:28.039 --> 00:00:29.879
<v Speaker 1>I'm happy to say that we have the whole hotel

9
00:00:29.920 --> 00:00:32.439
<v Speaker 1>this year because we have to accommodate I think just

10
00:00:32.479 --> 00:00:35.759
<v Speaker 1>over now a thousand people. Having said that, we are

11
00:00:35.759 --> 00:00:39.479
<v Speaker 1>doing a series and like little vignettes on covering different

12
00:00:39.479 --> 00:00:43.280
<v Speaker 1>aspects of the conference. This is a celebration year of

13
00:00:43.320 --> 00:00:46.200
<v Speaker 1>bringing innovation. Well, in this case, it's really going to

14
00:00:46.200 --> 00:00:48.119
<v Speaker 1>be from the trenches, which is the theme of this

15
00:00:48.159 --> 00:00:52.759
<v Speaker 1>particular podcast. But what is DEFARM about. Really, It's about,

16
00:00:52.920 --> 00:00:55.679
<v Speaker 1>in its simplest form, how can we disrupt the way

17
00:00:55.679 --> 00:01:00.399
<v Speaker 1>we do clinical research to make trials more efficient, more accessible,

18
00:01:00.920 --> 00:01:05.920
<v Speaker 1>more inclusive, less expensive, and ultimately far more patient centric

19
00:01:06.560 --> 00:01:09.640
<v Speaker 1>and hopefully site centric. Right, So those are the goals

20
00:01:09.640 --> 00:01:12.439
<v Speaker 1>that DEFARM has when every year has to raise the

21
00:01:12.480 --> 00:01:15.319
<v Speaker 1>bar to reach those goals. And our job is to

22
00:01:15.359 --> 00:01:18.319
<v Speaker 1>report on innovation. What are people doing that they're really

23
00:01:18.359 --> 00:01:20.560
<v Speaker 1>proud of that's been working for them, that they can

24
00:01:20.599 --> 00:01:23.760
<v Speaker 1>share with industry, and that's that's what we bring forward

25
00:01:23.760 --> 00:01:28.040
<v Speaker 1>at DEFARM. So if you all remember David Letterman's Top

26
00:01:28.079 --> 00:01:30.680
<v Speaker 1>ten list, I'm going to ask Tracy and challenge Tracy

27
00:01:30.760 --> 00:01:34.760
<v Speaker 1>to give us the sixteen sessions really short, like thirty

28
00:01:34.799 --> 00:01:39.319
<v Speaker 1>seconds or less, on what's happening with Fharma from the Trenches,

29
00:01:39.840 --> 00:01:42.400
<v Speaker 1>which is always featured on day one, in this case

30
00:01:42.439 --> 00:01:49.280
<v Speaker 1>September sixteenth, and it features sixteen sessions on representing companies

31
00:01:50.079 --> 00:01:53.159
<v Speaker 1>all pharma on something they're doing very special that they

32
00:01:53.200 --> 00:01:56.840
<v Speaker 1>want to share to help people in clinical trial operations.

33
00:01:56.879 --> 00:02:00.000
<v Speaker 1>So I'm setting up the scene for folks, and Trey

34
00:02:00.200 --> 00:02:02.120
<v Speaker 1>going to hand it over to you to go through

35
00:02:02.640 --> 00:02:07.159
<v Speaker 1>the sixteen sessions really really briefly, like what's the company

36
00:02:07.560 --> 00:02:10.199
<v Speaker 1>and what are they going to deliver our share? So

37
00:02:10.639 --> 00:02:12.840
<v Speaker 1>we're going to start with number sixteen and go for it.

38
00:02:12.879 --> 00:02:14.879
<v Speaker 1>And by the way, folks, this is not like with

39
00:02:15.000 --> 00:02:18.520
<v Speaker 1>David Letterman's Top ten, like the number one is like whatever.

40
00:02:18.599 --> 00:02:21.159
<v Speaker 1>The most outrageous. This is not that this is just

41
00:02:21.240 --> 00:02:24.599
<v Speaker 1>sixteen and there's nothing in particular order. It's just we

42
00:02:24.680 --> 00:02:27.039
<v Speaker 1>have sixteen of them, So go ahead, Tracy, to take

43
00:02:27.080 --> 00:02:27.479
<v Speaker 1>it away.

44
00:02:28.080 --> 00:02:31.680
<v Speaker 2>We have Amgen reporting on their custom built AI tool

45
00:02:31.719 --> 00:02:35.759
<v Speaker 2>to advance clinical trial operations. Mind Men on their use

46
00:02:35.800 --> 00:02:39.520
<v Speaker 2>of large language models for reader oversight in clinical trials

47
00:02:39.520 --> 00:02:44.159
<v Speaker 2>for efficiency and quality. Pfizer on an evaluation framework for

48
00:02:44.599 --> 00:02:49.159
<v Speaker 2>using Genitor AI safety and quality focus, gen Map on

49
00:02:49.199 --> 00:02:52.960
<v Speaker 2>a homegrown AI tool that accelerates safety surveillance.

50
00:02:53.240 --> 00:02:54.240
<v Speaker 1>Right, that's our first four.

51
00:02:54.439 --> 00:02:58.639
<v Speaker 2>We have Roach looking at their process for optimizing protocol

52
00:02:58.680 --> 00:03:03.400
<v Speaker 2>and ements across the portfolio. Vertex reporting on predictive analytics

53
00:03:03.439 --> 00:03:07.439
<v Speaker 2>and gen AI solutions in clinical trial operations and update

54
00:03:07.479 --> 00:03:11.439
<v Speaker 2>to their twenty twenty three presentation. Gilead on the use

55
00:03:11.439 --> 00:03:14.759
<v Speaker 2>of AI and designing, planning and monitoring the performance of

56
00:03:14.800 --> 00:03:18.599
<v Speaker 2>clinical trials at scale. Moderna on its framework for end

57
00:03:18.639 --> 00:03:22.479
<v Speaker 2>to end planning and forecasting really focused on breaking down

58
00:03:22.520 --> 00:03:26.520
<v Speaker 2>silos and streamlining operations across clinical trial operations.

59
00:03:27.159 --> 00:03:30.360
<v Speaker 1>Okay, so that's our second four. Okay, eight down, eight

60
00:03:30.400 --> 00:03:34.680
<v Speaker 1>to go go for it. Buysor on its next generation EDC.

61
00:03:34.479 --> 00:03:38.759
<v Speaker 2>SLASH CDMs platform that they're co developing with a tool provider,

62
00:03:39.479 --> 00:03:44.120
<v Speaker 2>Santafie on leveraging EHR data at scale to speed patient recruitment.

63
00:03:44.759 --> 00:03:50.759
<v Speaker 2>Findser on scaling DCT adoption XUS globally, Daichi Sankyo on

64
00:03:50.879 --> 00:03:54.439
<v Speaker 2>its homegrown clinical operations dash forward and metrics.

65
00:03:54.800 --> 00:03:56.520
<v Speaker 1>Okay, so I think we got four more to go.

66
00:03:58.560 --> 00:04:04.039
<v Speaker 2>Regeneron on its use of AI and surveys and to

67
00:04:04.199 --> 00:04:08.280
<v Speaker 2>call public and private data for patient insights to use

68
00:04:08.280 --> 00:04:11.439
<v Speaker 2>those in clinical trial design, Booking your angle time on

69
00:04:11.719 --> 00:04:16.959
<v Speaker 2>its process for rethinking change management to accelerate innovation adoption

70
00:04:17.079 --> 00:04:21.879
<v Speaker 2>at sites bias. Then on a novel screening ID mechanisms

71
00:04:21.879 --> 00:04:27.199
<v Speaker 2>it's home grown to drive patient recruitment. And here on

72
00:04:27.600 --> 00:04:33.120
<v Speaker 2>its proactive engagement strategies for driving future adoption of digital biomarkers.

73
00:04:33.319 --> 00:04:36.360
<v Speaker 1>All right, nice, So that's our sixteen sessions for Farmer

74
00:04:36.399 --> 00:04:39.920
<v Speaker 1>from the Trenches, Tracy, Thanks so much again. Defarm September

75
00:04:39.959 --> 00:04:44.120
<v Speaker 1>sixteenth and seventeenth in Philadelphia, And to get more information,

76
00:04:44.319 --> 00:04:48.079
<v Speaker 1>just visit our website and at the conferenceform dot org,

77
00:04:48.279 --> 00:04:51.600
<v Speaker 1>or you could go right to I think it's defarmconference

78
00:04:51.639 --> 00:04:54.360
<v Speaker 1>dot com. All right, thank you so much